Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study

Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study

IntroductionFour approved immune-based combinations for untreated metastatic renal carcinoma have demonstrated survival benefits. The ARON-1 study (NCT05287464) analyzed real-world data of patients with metastatic renal cell carcinoma receiving first-line immuno-oncology combinations. This sub-analy...

Full description

Saved in:
Bibliographic Details
Main Authors: Maria T. Bourlon, Luca Galli, Enrique Grande, Se Hoon Park, Bohuslav Melichar, Timothy J. Schieber, Maria José Juan-Fita, Yüksel Ürün, Javier Molina-Cerrillo, Teresa Alonso-Gordoa, Ugo De Giorgi, Jakub Kucharz, Esther Pérez Calabuig, Vincenza Conteduca, Tarek Taha, Pasquale Rescigno, Hussam Abu-Sini, Gian Paolo Spinelli, Ray Manneh Kopp, Alessia Salfi, Dipen Bhuva, Paola Valdez-Sandoval, Sofia Mendez-Bribiesca, Ondrej Fiala, Sebastiano Buti, Fernando Sabino Marques Monteiro, Aristotelis Bamias, Marwan Ghosn, Francesco Massari, Jawaher Ansari, Matteo Santoni
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Oncology
Subjects:
nivolumab plus cabozantinib
real-world evidence
metastatic renal cell carcinoma
clear cell renal cell carcinoma
non-clear cell renal cell carcinoma
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1605282/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items